An effective malaria vaccine is needed to address the public health tragedy resulting from the high levels of morbidity and mortality caused by Plasmodium parasites. The first protective immune mechanism identified in the irradiated sporozoite vaccine, the "gold standard" for malaria preerythrocytic vaccines, was sporozoiteneutralizing antibody specific for the repeat region of the surface circumsporozoite ( There is a critical need for an effective malaria vaccine, as standard public health measures have been eroded by drug resistance of the parasite and insecticide resistance of the mosquito vector. Moreover, traditional control measures have failed to prevent Plasmodium infections in 300 to 600 million people worldwide, resulting in over 1 million deaths each year (55). Vaccines remain the most cost-effective means for control of infectious diseases. Over the past 30 years, an effective malaria vaccine, based on attenuated sporozoites delivered by the bites of irradiated infected mosquitoes, has been shown to elicit sterile immunity in experimental animal models and human volunteers (11, 25, 27, 45) . However, large-scale production of an attenuated parasite vaccine faces significant practical limitations and logistical and regulatory hurdles that must be overcome. Sporozoites cannot be grown in culture and must be dissected from the salivary glands of infected mosquitoes that have fed on blood-stage parasites cultivated in human red blood cells. Additional challenges for attenuated sporozoite vaccines relate to cost, scale-up production, sterility, cold-chain storage, and route of immunization, which in humans has thus far been obtained only by exposure to the bites of irradiated infected mosquitoes. Nevertheless, the ability to elicit sterile protection following immunization with attenuated sporozoites provides a gold standard for development of subunit malaria vaccines that target the preerythrocytic stages of the parasite and effectively prevent initiation of the blood-stage infection responsible for clinical disease.
There is a critical need for an effective malaria vaccine, as standard public health measures have been eroded by drug resistance of the parasite and insecticide resistance of the mosquito vector. Moreover, traditional control measures have failed to prevent Plasmodium infections in 300 to 600 million people worldwide, resulting in over 1 million deaths each year (55) . Vaccines remain the most cost-effective means for control of infectious diseases. Over the past 30 years, an effective malaria vaccine, based on attenuated sporozoites delivered by the bites of irradiated infected mosquitoes, has been shown to elicit sterile immunity in experimental animal models and human volunteers (11, 25, 27, 45) . However, large-scale production of an attenuated parasite vaccine faces significant practical limitations and logistical and regulatory hurdles that must be overcome. Sporozoites cannot be grown in culture and must be dissected from the salivary glands of infected mosquitoes that have fed on blood-stage parasites cultivated in human red blood cells. Additional challenges for attenuated sporozoite vaccines relate to cost, scale-up production, sterility, cold-chain storage, and route of immunization, which in humans has thus far been obtained only by exposure to the bites of irradiated infected mosquitoes. Nevertheless, the ability to elicit sterile protection following immunization with attenuated sporozoites provides a gold standard for development of subunit malaria vaccines that target the preerythrocytic stages of the parasite and effectively prevent initiation of the blood-stage infection responsible for clinical disease.
In contrast to whole parasites, peptide vaccines can be readily synthesized from inexpensive, well-defined amino acid components and lyophilized for storage and transport. In recent years, peptide immunotherapeutics have been developed for human autoimmune diseases and allergies (21, 31) , and peptide subunit vaccines for infectious diseases and treatment of cancer have been tested in clinical trials (3, 24, 32, 33, 52) . The first phase I/II trial of a malaria synthetic peptide vaccine was carried out over 20 years ago to assess the efficacy of a peptide-protein conjugate vaccine, termed (NANP) 3 -TT, comprised of the immunodominant B-cell repeat epitope (NANP) 3 from the Plasmodium falciparum major surface circumsporozoite (CS) protein linked to tetanus toxoid (TT) as the protein carrier (26) . Exposure of a small number of (NANP) 3 -TTimmunized volunteers to the bites of P. falciparum-infected mosquitoes demonstrated that the vaccine could elicit protective antibody responses against P. falciparum sporozoites. However, the lack of malaria T-cell epitopes in the (NANP) 3 -TT conjugate vaccine limited the ability of the host to mount anamnestic T-cell responses following sporozoite challenge (14, 23) .
Subsequent studies using a CD4 ϩ -T-cell clone from a volunteer immunized with irradiated P. falciparum sporozoites identified a CD4
ϩ -T-cell epitope, termed T1, within the 5Ј minor repeat region of P. falciparum CS protein (41) . A branched peptide containing the T1 and the (NANP) 3 B-cell epitopes from the P. falciparum CS repeat region, termed (T1B) 4 multiple-antigen peptide, provided a macromolecular construct which did not require a foreign protein carrier and which was highly immunogenic in preclinical studies and in human volunteers (16, 37, 43) . However, the T1 Th epitope contained in the vaccine was genetically restricted and recognized by inbred strains of mice and human volunteers expressing a limited number of major histocompatibility complex class II genotypes (38, 43) .
The genetic restriction of vaccine-induced anti-CS repeat antibody responses was subsequently overcome by inclusion of a universal Th epitope derived from the P. falciparum CS protein (6, 36) . This epitope, termed T*, was originally identified using CD4
ϩ T cells of volunteers protected against challenge following immunization with irradiated P. falciparum sporozoites and was considered "universal" based on its ability to bind to a broad range of murine and human class II molecules. In a small phase I trial, a tetrabranched triepitope peptide vaccine, termed (T1BT*) 4 -P3C, comprised of P. falciparum CS repeat epitopes T1 and B synthesized in tandem with the universal T* epitope, elicited antirepeat antibody and CD4
ϩ -T-cell responses in volunteers of diverse class II haplotypes (40) . The fine specificity and function of CD4 ϩ -T-cell clones derived from the (T1BT*) 4 -P3C-immunized volunteers were comparable to those of clones derived from volunteers immunized with irradiated P. falciparum sporozoites (7, 36) . Consistent with the broad genetic restriction of the universal T-cell epitope, the majority of CD4 ϩ T cells in both the peptide-and sporozoite-immunized volunteers were specific for the T* epitope, with few clones recognizing the CS repeat epitopes. The T*-specific clones from both peptide-and sporozoite-immunized volunteers secreted high levels of gamma interferon (IFN-␥), a potent inhibitor of intracellular hepatic stages of the Plasmodium parasite (20, 34, 53) . While the branched synthetic peptide containing P. falciparum CS T-and B-cell epitopes was safe and immunogenic in clinical trials (40, 43) , scale-up synthesis of large quantities of branched peptides has presented significant technical challenges for vaccine development.
It has been shown in various experimental models of infectious diseases that linear peptides containing strong T-cell epitopes can be highly immunogenic. In rodent malaria, linear peptides containing a combination of malaria epitopes and universal T-helper epitopes, derived from either tetanus toxoid or an artificial pan-DR binding epitope, were as immunogenic as branched peptides containing the same sequences (1, 10, 15, 22, 64) . However, the use of foreign protein or nonnatural universal epitopes limits the potential of linear peptides, since they would not elicit parasite-specific memory T-cell anamnestic responses in naturally infected individuals, and vaccineinduced responses would not be boosted following exposure to bites from infected mosquitoes.
We therefore determined whether the presence of the P.
falciparum-specific universal T-cell epitope, T*, would overcome the need for a branched configuration and produce an immunogenic linear peptide. The immunogenicity of the triepitope T1BT* sequence, containing the T* epitope combined with the T1 and B repeats and synthesized either as a linear or a branched construct, was determined in mice and Aotus nancymaae monkeys using adjuvants acceptable for human use. These studies provide the first demonstration that a 48-mer linear peptide containing the P. falciparum universal T* epitope and CS repeats is highly immunogenic and, importantly, can elicit protective immunity against viable sporozoite challenge mediated by antibodies specific for P. falciparum CS repeats.
MATERIALS AND METHODS
Peptides. The T1 epitope (DPNANPNV) 2 is located in the 5Ј minor repeat and the B epitope (NANP) 3 in the 3Ј major repeat of the central repeat region of the P. falciparum CS protein (NF54 isolate) (Fig. 1) . The universal T* epitope, EYLNKIQNSLSTEWSPCSVT, is located in the C terminus of the P. falciparum CS protein (6, 36) and overlaps a highly conserved region of the CS protein that functions in targeting the sporozoite to the liver (8) . The T1BT* sequence (DPNANPNV) 2 (NANP) 3 EYLNKIQNSLSTEWSPCSVT was synthesized as a 48-mer linear peptide or as a tetrabranched (T1BT*) 4 peptide containing the triepitope sequence in each branch (39, 40) (Fig. 1) . Synthetic peptides containing the individual T1, B, and T* epitopes (AnaSpec, Inc.) were used as antigens in cellular assays. Peptide purity was 95 to 99%, as determined by reverse-phase high-pressure liquid chromatography. The composition of each peptide was confirmed by amino acid analysis.
Adjuvants. The immunogenicity of peptides formulated in Freund's complete adjuvant, with boosters in Freund's incomplete adjuvant, was compared with that of peptides administered in adjuvants suitable for human use. These adjuvants included the water-in-oil Montanide ISA 51, a highly purified mineral oil emulsion comparable to Freund's incomplete adjuvant, and ISA 720, a natural metabolizable nonmineral oil and a highly refined emulsifier of the mannide monooleate family (Seppic, Inc.) (2); MF59, a squalene-water emulsion (Chiron Corp.) (50) , and C57BL/10 (H-2 b ) mice (Jackson Labs, Bar Harbor, ME, and Taconic Farms, NY) were used to assay the immunogenicity of branched versus linear peptides. Mice in each group (n ϭ 3 to 4) were immunized subcutaneously with three doses of 50 g of peptide at 20-to 30-day intervals. Peptide dosage was chosen based on previous murine and monkey studies using branched synthetic peptides as immunogens (37) (38) (39) . Individual mice in each group were bled before immunization and 22 days after each immunization for analysis of antirepeat antibody responses. All rodent studies were carried out with approval of the Institutional Animal Care and Use Committee.
Aotus monkeys. Aotus nancymaae monkeys were maintained at the Fundacion Instituto de Inmunologia de Colombia animal facility in Leticia, Colombia, in compliance with standards for Humane Care and Use of Laboratory Animals. Monkeys were quarantined for a 1-month conditioning period during which they were examined for concurrent infections and treated appropriately (37) . Animals positive for malaria infections by Giemsa-stained blood smears and/or by serology were excluded from the trial. Monkeys were immunized with 1 mg of linear or branched peptide at 3-week intervals administered at multiple subcutaneous injections in the ventral area, and blood was collected for sera prior to and 21 days after each immunization.
Antibody assays. The antirepeat immunoglobulin G (IgG) titers were determined by enzyme-linked immunosorbent assay (ELISA) using the (T1B) 4 peptide as antigen (AnaSpec, Inc.), enzyme-labeled species-specific anti-IgG antibody, and 2,2Ј-azinobis(3-ethylbenzthiazolinesulfonic acid) (ABTS) substrate (37) . Endpoint titers, defined as the last serum dilution having an optical density greater than the optical density ϩ 3 standard deviations of preimmune sera, were obtained for individual mice in each group and expressed as geometric mean titer (GMT).
Reactivity with parasites was determined by indirect immunofluorescence assay (IFA) using P. falciparum (NF54 isolate) sporozoites as the antigen and species-specific fluorescein isothiocyanate-labeled anti-IgG (Kierkegaard & Perry, Gaithersburg, MD). IFAs were carried out using twofold dilutions of pooled serum from each group of mice or individual serum from Aotus monkeys. Slides were coded to avoid bias, and the last dilution at which fluorescent parasites were observed was taken as the endpoint titer.
IFN-␥ ELISPOT. The number of IFN-␥-secreting cells in spleens of mice immunized with linear or branched peptides was measured by IFN-␥ enzymelinked immunospot (ELISPOT) assay (35) . Briefly, 3 ϫ 10 5 naïve or immune spleen cells were incubated overnight with irradiated spleen cells as antigenpresenting cells, either with or without T1BT* peptide, in nitrocellulose 96-well plates coated with monoclonal antibody (MAb) anti-IFN-␥ (R-6A2). Plates were washed and reacted with biotinylated anti-murine IFN-␥ (BD Pharmingen) followed by washing and staining with peroxidase-labeled streptavidin and 5-bromo-4-chloro-3-indolylphosphate-nitroblue tetrazolium membrane phosphatase substrate. The number of spot-forming cells (SFC) was counted by an ImmunoSpot Analyzer (CTL, Cleveland, OH), and results were expressed as the number of SFC/10 6 spleen cells. Transgenic sporozoites. Transgenic Plasmodium berghei rodent malaria parasites expressing P. falciparum CS repeats, termed PfPb, were used to assess biological activity of peptide-induced antirepeat specific immunity (49) . Immunized and naïve control mice were anesthetized and challenged by exposure to the bites of 10 to 15 PfPb-infected mosquitoes. Livers were removed 40 h postchallenge, and total RNA was extracted using a commercial kit (Invitrogen).
The amount of parasite rRNA in each liver was determined by reverse transcription and real-time PCR of cDNA using primers specific for 18S rRNA (5).
Results were expressed as the number of copies of parasite rRNA based on an 18S rRNA plasmid reference standard.
The mechanism of immune protection in peptide-immunized mice was determined by T-cell depletion prior to PfPb challenge of immunized mice. Mice were depleted of T cells by administration of MAb specific for CD4 (MAb GK1.5) or CD8 (MAb 2.43) on days Ϫ2 and Ϫ1 prior to challenge. Depletion of CD4 ϩ and CD8 ϩ T cells following MAb treatment was confirmed by fluorescence-activated cell sorter analysis (BD Pharmingen). Following challenge, the level of parasite 18S rRNA in livers of T-cell-depleted or intact immunized mice was determined using real-time PCR, as described above.
The function of antirepeat antibodies elicited in the peptide-immunized mice was determined using an in vitro transgenic sporozoite neutralization assay (TSNA), as previously described (29) with modifications. Preimmune or immune sera of peptide-immunized mice were incubated with 2 ϫ 10 4 PfPb sporozoites for 40 min on ice prior to addition to HepG2 cells grown to confluence in 48-well culture plates. After washing to remove sporozoites that did not invade, the cell cultures were incubated in complete RPMI containing 10% fetal calf serum for 48 h at 5% CO 2 . Cell cultures were trypsinized, and parasite rRNA levels were determined by real-time PCR, as described above. 4 versus linear T1BT* peptide. Peptide immunogens frequently require strong adjuvants, as they lack the pathogen-associated molecular pattern found in bacterial or viral antigens. Therefore, initial assays comparing the immunogenicity of the T1BT* linear peptide versus (T1BT*) 4 branched peptide were carried out using the potent Freund's adjuvant. Consistent with previous studies using the (T1BT*) 4 -P3C branched peptide (39), high anti-immunogen antibody titers were obtained in BALB/c and C57BL/10 mice immunized with the branched (T1BT*) 4 peptide in Freund's adjuvant (Table 1) . Importantly, the linear T1BT* peptide elicited equally high anti-immunogen titers in both strains of mice, with peak antibody titers of 163,840 to 327,680.
RESULTS

Immunogenicity of branched (T1BT*)
The fine specificities of the antibodies elicited by branched (T1BT*) 4 or linear T1BT* peptides were also similar in both strains and were predominantly directed against the CS repeat ( Table 1 ). The peptide-induced antirepeat titers elicited by both branched and linear peptide correlated with titers to P. falciparum sporozoites as measured by IFA. BALB/c mice (H-2 d ), which are nonresponders to CS repeats, developed peak ELISA and IFA titers similar to C57BL/10 (H-2 b ), which are high responders to CS repeats (14, 23, 38) . Therefore, the presence of multiple Th epitopes, i.e., within CS repeats and a Four mice/group were immunized by three injections of either the tetrabranched peptide or the linear peptide containing the T1BT* sequence. b Results are shown as the geometric mean ELISA endpoint titers for sera of four mice in each group obtained after the third immunization. ELISA plates were coated with either the branched peptide or the linear peptide used as the immunogen, the CS repeat (T1B) 4 peptide, or the nonrepeat (T*) 4 peptide. Titers for all preimmune sera were Ͻ80.
c IFA titers against P. falciparum sporozoites were determined using pooled serum from each group of mice.
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T* epitope, did not affect the magnitude of the antirepeat or antisporozoite antibody responses elicited by linear peptide. While the antirepeat antibodies predominated, antibodies to the T* epitope were also detected in the peptide-immunized mice, depending on the immunogen and murine strain. All of the mice immunized with the branched peptide developed anti-T* antibodies, reaching peak titers of 5,120 in BALB/c and 20,480 in C57BL/10 mice. In contrast, the response to linear peptide was mainly to CS repeats, and significantly lower anti-T* antibody in BALB/c (1,280 titer) and no antibodies to T* in C57BL/10 (Ͻ80) were detected.
Immunogenicity of linear peptides requires the universal epitope. The immunogenicity of the linear peptide was dependent on Th provided by the universal T* epitope. BALB/c mice, which are nonresponders to both the T1 and B repeats but high responders to the T* epitope (6, 38) , developed high antirepeat antibodies when immunized with the linear peptide ( Table 1) .
To determine if other CS-derived Th epitopes could substitute for the universal T* epitope and overcome the requirement for a branched peptide configuration, C57BL/10 and C3H mice were immunized with linear or branched peptides containing only the T1 and B repeat sequences. Both C57BL/10 (H-2 b ) and C3H (H-2 k ) mice can recognize Th epitopes within the T1 minor repeat, and C57BL/10 mice can also recognize Th epitopes within the (NANP) n major repeat region (14, 23, 38) .
When administered in Freund's adjuvant, the branched (T1B) 4 peptide elicited high antibody titers in C57BL/10 mice and also positive, although lower, antibody responses in C3H mice (Fig. 2, left panel) , consistent with previous studies (38) . However, the presence of the allele-specific T1 Th epitope was not sufficient to overcome the requirement for a branched configuration. Minimal or no antibodies were observed when the mice were immunized with linear T1B peptide (Fig. 2, right  panel) . These results indicate that the immunogenicity of linear peptides was dependent on the presence of the strong T* universal T-cell epitope.
Linear versus branched peptides formulated in adjuvants suitable for humans. The immunogenicity of linear peptides was comparable to that of branched peptides when administered in Freund's, a potent adjuvant which is not acceptable for human use. The peptides were therefore tested in various adjuvants suitable for human vaccines, including the water-inoil adjuvants Montanide ISA 51 and ISA 720, the oil-in-water adjuvant MF59, and a CpG oligodinucleotide, and results were compared to peptide without adjuvant (PBS).
In the absence of adjuvant, the immunogenicity of the linear and branched peptides differed, depending on the murine strain. In C57BL/10 mice, both branched and linear peptides were immunogenic in the absence of adjuvant, eliciting antirepeat titers of 10 3 to 10 4 copies when administered in PBS (Fig. 3) . In contrast, in BALB/c mice only the branched (T1BT*) 4 peptide was immunogenic in the absence of adjuvant.
Addition of adjuvant increased antibody titers 1 to 2 logs higher than those elicited by peptide in PBS. Branched peptide formulated in Montanide ISA 720, ISA 51, or CpG adjuvants elicited antirepeat ELISA and IFA titers of 10 4 to 10 5 in both C57BL/10 and BALB/c mice (Fig. 3A) . Similar results were obtained with MF59 adjuvant in C57BL/10 mice. In contrast, the antibody response to linear peptide was more adjuvant dependent (Fig. 3B) . In both strains of mice, optimal levels of antibodies were obtained with linear peptides formulated in ISA 51 or ISA 720 adjuvant, reaching peak titers equal to or greater than those obtained with Freund's adjuvant formulations ( Table 1 ). The magnitude of antibody induced by linear T1BT* in ISA 720 or ISA 51 was equivalent to that obtained with the branched peptide administered in the same adjuvants. However, in contrast to the oil emulsion adjuvants, CpG-formulated linear peptide was less immunogenic than branched peptides in C57BL/10 mice and poorly immunogenic in BALB/c mice.
For all adjuvant formulations, antirepeat antibody titers elicited by either linear or tetrabranched peptide correlated with reactivity with P. falciparum sporozoites as measured by IFA (Fig. 3, dark versus hatched bars) . These results indicate that neither the peptide configuration nor the adjuvant formulation altered the peptide-induced antirepeat antibody cross-reactivity with native CS protein on sporozoites.
Antibody IgG subtypes. The linear and branched peptides, either with or without adjuvant, elicited a predominantly Th2 type IgG1 antirepeat antibody response (Fig. 4) . Predominance of IgG1 antibody subtype was also observed in sera of mice immunized with peptides in oil-in-water adjuvant MF59 and oligonucleotide dinucleotide CpG (data not shown).
The ability to elicit a mixed Th1/Th2 response varied between the strains of mice and was independent of peptide configuration. BALB/c mice immunized with either branched or linear peptide, administered in water-in-oil adjuvants (Freund's, ISA 720, or ISA 51), developed Th1 type IgG2a antibodies. In contrast, only low levels of IgG2a antibodies were detected in sera of peptide-immunized C57BL/10 mice. Adjuvant was critical for induction of Th1 type responses to linear peptide, as mice immunized with linear peptides in the absence of adjuvant did not develop IgG2a antirepeat antibodies. 4 peptide or linear T1B peptide containing Th epitopes from the CS repeat region. Previous studies have shown that C57BL/10 mice recognize Th epitopes within the minor and major CS repeats, termed T1 and B, respectively, while C3H mice recognize Th epitopes only within the T1 minor repeats (14, 23, 38) . Antirepeat antibody ELISA titers were measured in individual sera of C57BL/10 (solid bars) or C3H (hatched bars) mice (n ϭ 3 mice/group). Mice were immunized with three injections of either branched (T1B) 4 peptide or linear T1B peptide using Freund's adjuvant.
FIG. 2. Immunogenicity of branched (T1B)
Cellular responses elicited by branched versus linear peptides.
The cellular responses elicited by the T1BT* branched or linear peptide formulated in the optimal Montanide ISA 720 adjuvant were evaluated by IFN-␥ ELISPOT assay. Immunization of C57BL/10 mice with branched (T1BT*) 4 peptide induced high levels of IFN-␥-secreting cells (Fig. 5) . Importantly, similar levels of IFN-␥-secreting cells were also observed in spleen cells of mice immunized with T1BT* linear peptide. Responses were specific for malaria peptides, as minimal IFN-␥ SFC were found in spleen cells of naïve mice or mice immunized with ISA 720 adjuvant only.
Immunogenicity of linear peptides in Aotus monkeys. While comparable levels of immune responses were observed in the inbred mice immunized with branched or linear peptide, no information was available on the immunogenicity of small linear peptides in larger animals of diverse genetic background. Outbred Aotus nancymaae monkeys were therefore immunized with the T1BT* linear or branched peptides in different adjuvant formulations.
Aotus monkeys immunized with (T1BT*) 4 -P3C branched peptide developed positive antibody responses detected by ELISA and IFA (Fig. 6 ). These antibody titers were of the same magnitude as those found in human volunteers immunized with this vaccine formulation (40) , which suggests that this Aotus model may be relevant for preclinical analysis of potential vaccine constructs. Similar levels of antirepeat antibody titers (Fig. 6 , hatched bars) and IFA titers (Fig. 6 , solid bars) were obtained in Aotus monkeys immunized with the (T1BT*) 4 branched peptide administered in Freund's.
Importantly, three monkeys immunized with the linear peptide T1BT* administered in Montanide ISA 51 developed high antirepeat and antisporozoite antibody titers, with GMT of 32,510 and 51,606, respectively. These titers were comparable to those observed in the monkeys immunized with the tetrabranched peptide (T1BT*) 4 -P3C, which reached peak GMT of 81,920 in ELISA and 28,963 by IFA.
Protective immunity induced by linear peptides. Aotus monkeys, as well as other nonhuman primates, are poorly susceptible to P. falciparum sporozoites, which limits the ability to determine the protective efficacy of immune responses elicited by the peptide vaccines. We therefore utilized a transgenic P. berghei rodent parasite, termed PfPb, in which the homologous P. berghei CS repeat region was replaced with the P. falciparum CS repeat region (29, 49) . These transgenic sporozoites are functionally rodent parasites, infecting mice in vivo and hepatoma cells in vitro, but are antigenically P. falciparum, since they express the immunodominant P. falciparum repeat region, thus providing a means to assay the inhibitory activity of vaccine-induced anti-P. falciparum repeat responses.
Mice immunized with branched or linear peptide in 
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Freund's or ISA 720 adjuvant were challenged by exposure to the bites of mosquitoes infected with the transgenic PfPb parasites. In four control mice receiving only Freund's adjuvant, parasite rRNA was detectable in livers at 40 h postchallenge (Fig. 7A ). In contrast, the level of parasite rRNA was reduced 61% in livers of four mice immunized with branched peptides (T1BT*) 4 -Freund's adjuvant (P ϭ 0.01) and 95% in mice immunized with (T1BT*) 4 -P3C (P ϭ 0.002) compared to control mice. Importantly, the level of hepatic parasite rRNA was reduced 96% in mice immunized with the T1BT* linear peptide administered in Freund's adjuvant (P ϭ 0.004). When peptides were tested in an adjuvant acceptable for human use, Montanide ISA 720, protection against viable sporozoite challenge was also obtained (Fig. 7B) . At 40 h after PfPb sporozoite challenge, parasite rRNA levels were reduced 90% in the mice immunized with branched peptide (T1BT*) 4 -ISA 720 compared to adjuvant control (P ϭ 0.04). The linear peptide was as effective as branched peptide in protecting against a natural sporozoite challenge delivered by the bite of infected mosquitoes. Mice immunized with T1BT* linear peptide in ISA 720 demonstrated a reduction of 97% of hepaticstage development (P ϭ 0.01). Of particular importance, in three of the four mice immunized with T1BT*-ISA 720, there was no parasite rRNA detectable in the liver as measured by (Table 1 and Fig. 3 ) as well as peptide-specific cells that produced IFN-␥ (Fig. 5) , a potent inhibitor of exoerythrocytic form development (20, 53) . Therefore, CS-specific cells and/or antibodies could potentially function in protection against PfPb challenge in mice immunized with T1BT* linear peptide.
To explore the role of T-cell-mediated immunity, in a second experiment, mice immunized with T1BT* linear peptide in ISA 720 were depleted of CD4 ϩ or CD8 ϩ T cells prior to challenge. In the nondepleted mice immunized with T1BT*-ISA 720, mean parasite rRNA levels were reduced 85% (5,060 Ϯ 9,809 copies) compared to control mice (35,102 Ϯ 14,380 copies) (P ϭ 0.007) (Fig. 8A) . Three of four of the immunized mice were totally protected, with a mean rRNA copy number of 156 Ϯ 47, similar to the noparasite control (189 Ϯ 95 copies).
Depletion of CD4 ϩ or CD8 ϩ T cells prior to challenge did not abrogate immune resistance. Parasite levels were reduced 98% (mean number of rRNA copies, 826 Ϯ 1,369) and 99% (mean number of rRNA copies, 200 Ϯ 110) in the livers of CD4 ϩ -and CD8 ϩ -T-cell-depleted immune mice, respectively, which was not significantly different from the level of protection observed in the nondepleted immunized mice (P ϭ 0.2). Three of four mice in the anti-CD4 MAb-treated group and four of four mice in the anti-CD8 MAb-treated group had Ͻ350 rRNA copies detectable by PCR, similar to the noparasite control, indicating that the mice were totally protected. Therefore, resistance to PfPb sporozoite challenge in the T1BT* linear peptide-immunized mice did not require the presence of repeat-specific T cells.
To determine the role of antibodies, the serum from the peptide-immunized mice was tested for biological activity using an in vitro TSNA (29) . Compared to day 0 sera, the sera of eight mice immunized with T1BT*-ISA 720 significantly blocked sporozoite invasion of hepatoma cells (Fig. 8B) . For all eight sera, the mean number of rRNA copies in cultures receiving sporozoites incubated in day 0 serum was 34 ϫ 10 6 Ϯ 17 ϫ 10 6 , compared to 0.4 ϫ 10 6 Ϯ 0.9 ϫ 10 6 rRNA copies in cultures containing sporozoites incubated with immune serum (P ϭ 0.001). The sporozoite-neutralizing activity in the immune sera correlated with the high levels of antirepeat antibodies that developed in all of the C57BL mice immunized with T1BT*-ISA 720 (mean titer, 54,613; range, 20,480 to 163,840). The presence of strong sporozoite-neutralizing activity in sera of all of the peptide-immunized mice, combined with the failure of T-cell depletion to abrogate immune resistance, indicates that protection elicited by linear peptide was mediated by high levels of antirepeat antibodies. 
DISCUSSION
Recent studies based on CS transgenic mice have shown that the CS protein is a primary target of immune responses elicited by irradiated sporozoites (48a), the "gold standard" for preerythrocytic-stage vaccine development. Although CD8 ϩ T cells play a critical role in sporozoite-induced immunity in some murine strains (19, 65) , we have shown that sporozoiteimmunized mice lacking CD8 ϩ T cells can develop high levels of sterile immunity mediated by antibody and CD4 ϩ T cells (G. A. Oliveira and E. H. Nardin, submitted for publication).
Antibodies specific for the immunodominant repeat region of the CS protein were the first immune mechanism identified in the sporozoite-immunized host (48) . In early studies, incubation of sporozoites of rodent, simian, or human species of Plasmodium with immune sera containing antirepeat antibodies led to loss of infectivity, as determined by the failure of the incubated sporozoites to induce a patent infection when injected into a susceptible host (12, 42, 46) . Antirepeat antibodies neutralize sporozoite infectivity by blocking parasite-host cell interactions in the liver and inhibiting sporozoite motility required for hepatocyte invasion (8, 57, 59) . Recent intravital microscopy studies have shown that antirepeat antibodies also immobilize extravascular sporozoites at the site of the mosquito bite and prevent their egress into the circulation and transit to the target cells in the liver (62) . Antibodies can also enhance phagocytosis of sporozoites, and the presence of opsonizing antibodies specific for CS repeats has been correlated with protection in volunteers immunized with a CS subunit vaccine (13, 47, 54) .
In a phase I trial, a triepitope branched synthetic peptide, (T1BT*) 4 -P3C, comprised of the P. falciparum CS protein universal T* epitope synthesized in tandem with CS repeats, was shown to be safe and immunogenic (40) . This branched peptide elicited antisporozoite antibodies and CD4 ϩ T cells with fine specificity and function comparable to those found in volunteers immunized by irradiated P. falciparum sporozoites (7, 36) . In the current studies, a 48-mer linear peptide containing these minimal P. falciparum CS T-and B-cell epitopes was as immunogenic as a branched peptide when tested in inbred strains of mice and outbred nonhuman primates. This simple T1BT* linear peptide elicited sporozoite-neutralizing antibodies and protection against viable sporozoite challenge comparable to levels obtained by immunization with the more complex (T1BT*) 4 tetrabranched peptide.
In early vaccine studies, peptides containing P. falciparum CS repeat epitopes were poorly immunogenic, and optimal immune responses required conjugation to carrier proteins or synthesis as macromolecular branched peptides (9, 61, 66) . Phase I trials have demonstrated the safety and immunogenicity of the first-generation P. falciparum CS repeat peptideprotein conjugate, (NANP) 3 -TT (26) , and branched peptides containing CS repeats either alone [(T1B) 4 multiple-antigen peptide] or combined with the universal T* epitope [(T1BT*) 4 -P3C] (40, 43) . While the highest levels of antibody were elicited with the branched peptides, the technical challenges of synthesizing large quantities of homogeneous, physiochemically characterized branched peptides prevented scale-up for production of vaccines.
In the current studies, we show that incorporation of the P. falciparum CS universal T* epitope overcomes the requirement for a branched configuration, providing a highly immunogenic linear peptide vaccine. Consistent with previous studies using foreign protein or artificial universal Th cell epitopes (10, 22, 63) , the inclusion of the strong P. falciparum CS universal T* epitope was essential for immunogenicity of the linear CS peptide. Other CS-derived Th epitopes could not substitute for the universal T* epitope, as shown by the failure of linear peptides containing the CS repeat T1 Th epitope to elicit immune responses in C57BL/10 or C3H mice (Fig. 2) . The T1 Th epitope, in contrast to the T* universal epitope, is recognized by only a limited number of HLA class II genotypes in mice and humans (6, 38, 43) . While the mechanism by which universal epitopes overcome peptide configuration requirements remains to be defined, the presence of multiple overlapping T-cell epitopes within the universal T* epitope (6, 7, 36) may elicit a broad range of Th cells to enhance the immunogenicity of linear peptides.
While comparable levels of antirepeat antibodies were induced by branched or linear peptides, the fine specificity of the antipeptide antibody responses differed. Branched peptide elicited antibody to the T* epitope as well as to the repeat epitopes, while the linear peptide elicited significantly lower or no anti-T* antibody (Table 1) . Thus far, antibodies to nonrepeat epitopes of CS have not been shown to play a significant role in sporozoite immunity. The linear peptide may therefore be more effective than branched peptides in focusing immune responses on the functional CS repeats contained within the vaccine. Adjuvants are critical for peptide immunogenicity, as the absence of appropriate stimulus for maturation of dendritic cells may result in tolerogenic, rather than immunogenic, peptides (17, 56) . The 48-mer linear T1BT* peptide was immunogenic in all adjuvant formulations tested, including Freund's adjuvant and adjuvants suitable for human use. Formulation of the linear as well as the branched peptide in the water-in-oil adjuvants Montanide ISA 51 and ISA 720 elicited high levels of antirepeat antibodies in both strains of inbred mice. Consistent with murine responses, Aotus monkeys immunized with T1BT* linear peptide in ISA 51 developed antisporozoite antibody titers similar to those induced by branched peptide (T1BT*) 4 containing either the P3C lipopeptide or Freund's adjuvant (Fig. 6) . The finding that outbred Aotus monkeys immunized with (T1BT*) 4 However, studies in Aotus monkeys, as well as human phase I trials, provide limited information on the biological function of the immune responses elicited by P. falciparum peptide vaccines. In the current studies, we demonstrate that mice immunized with branched (T1BT*) 4 , using either P3C lipopeptide adjuvant or Freund's adjuvant, were protected against challenge with PfPb sporozoites expressing P. falciparum CS repeats (Fig. 7A) . Importantly, mice immunized with the linear T1BT* peptide administered in ISA 720, an adjuvant suitable for human use, were also protected against challenge with viable PfPb sporozoites (Fig. 7B) . The presence of sporozoiteneutralizing antibodies in the sera of all the mice immunized with linear peptide (Fig. 8B) , and the failure of T-cell depletion to abrogate resistance (Fig. 8A) , indicates that protection against viable PfPb sporozoites was mediated by antibodies to P. falciparum CS repeats.
The predominance of Th2 type IgG1, a nonopsonizing antibody subtype, in the mice protected against challenge (Fig. 4) suggests that direct inhibition of sporozoites, rather than enhanced clearance and phagocytosis, was functioning in immune resistance. Consistent with a limited role for Fc-mediated immune effector mechanisms, immune sera from the mice immunized with linear peptide inhibited Ͼ98% of sporozoite invasion of hepatoma cells in vitro (Fig. 8B) .
In addition to antirepeat antibodies, protection against P. falciparum infection has been correlated with the presence of IFN-␥-producing CD4 ϩ T cells in vaccinated volunteers and naturally infected individuals living in Africa (51, 60). In the current studies, immunization with linear or branched triepitope peptide elicited comparable numbers of IFN-␥-producing T cells (Fig. 5) . Although the fine specificity of these cells remained to be defined, in humans immunized with either irradiated P. falciparum sporozoites or the (T1BT*) 4 -P3C branched peptide, the majority of IFN-␥-producing CD4
ϩ -Tcell clones were specific for the T* peptide, with minimal or no response to the CS repeats (7, 36) . In the Plasmodium yoelii rodent model, immunization with linear peptide containing non-CS malaria epitopes has been shown to elicit protective immunity against sporozoite challenge mediated by CD4 ϩ T cells producing IFN-␥ (10, 63) . The function of T cells specific for T* epitope, however, could not be assayed using the PfPb model, since the transgenic parasites express only the P. falciparum CS repeat region. Construction of transgenic parasites expressing the T* epitope is in progress to explore the in vivo function of T*-specific cells in mice immunized with linear peptide.
The antirepeat antibody-and IFN-␥-producing cellular responses demonstrated in this study suggest that a simple linear peptide, containing the CS repeats and the universal T* epitope, has the potential to elicit immune responses that target both the extracellular sporozoite and the intracellular hepatic stages. Efficacy would be further enhanced by combination with epitopes from other preerythrocytic-stage and/or blood-stage antigens to elicit antibodies to target merozoites released from exoerythrocytic forms. While CD8 ϩ T cells play critical roles in murine malaria models, an essential role for human CD8
ϩ -T-cell responses has not been demonstrated in subunit vaccine trials and naturally infected individuals (30, 51, 58) . Peptide vaccines eliciting strong class II-restricted CD4
ϩ -T-cell and antibody responses may therefore provide effective vaccines that can be readily optimized, in contrast to vaccines requiring both class I and class II antigen-presenting pathways.
The finding that branched peptide malaria vaccines were safe and well tolerated in phase I trials (40, 43) encourages the expectation that a linear peptide will demonstrate a similar safety profile. Synthetic peptides provide safety advantages over attenuated parasite or recombinant viral vector vaccines for vaccination of immunocompromised individuals, in addition to eliminating potential adventitious agents acquired during cell culture and the need for cold-chain storage, which significantly increase costs of attenuated vaccines. In recent years, immunotherapy with linear peptides has been used in treatment of autoimmune diseases and allergy (21, 31) , and the industrial standards for synthesis, characterization, and largescale production of peptides for clinical applications are well established. These factors encourage further development of linear peptides containing P. falciparum minimal T-and B-cell epitopes as cost-effective, safe, and easily produced malaria vaccines.
